The latest report from the Federal Trade Commission (FTC) has uncovered a disturbing trend in the healthcare industry - insurers are profiting handsomely from drug markups, to the tune of a staggering $7.3 billion.

This revelation sheds light on the opaque nature of the pharmaceutical supply chain and the pressing need for greater transparency and accountability.

The FTC's findings are a stark reminder of the complex web of intermediaries that drive up the cost of healthcare for patients.

Insurers, pharmacy benefit managers (PBMs), and drug manufacturers are all implicated in this practice, which ultimately undermines the affordability and accessibility of essential medications. - https://webmdnetwork.com/blog/insurers-drug-markups-7-3-billion/?unique_id_qx1j524s

Insurers' Lucrative Drug Markup Practices Exposed in FTC Report